Tag: O’Melveny

Which Chinese and international law firms have earned client trust through exceptional expertise?      

Alvin Sin joins Appleby as partner in Shanghai and legal manager in Hong Kong

Restructuring and insolvency expert Mark Fairbairn will join Linklaters’ Hong Kong office later this year as a senior consultant

O’Melveny, JunHe, MoFo, and Jingtian & Gongcheng aided TYK Medicines' USD74.3M debut on HKEX, the largest IPO under HK's Chapter 18A

China Business Law Journal reveals its top performing law firms of 2023

O'Melveny’s New York-based partner, Portia Ku, will succeed Walker Wallis, who retired on 30 June, as the new managing partner in the firm’s Shanghai office

O’Melveny, Global Law Office, Linklaters and Haiwen & Partners have clinched roles in Chinese jewellery brand Laopu Gold’s listing on the HKEX

O’Melveny’s M&A partner Alan Bao has joined White & Case’s Beijing office as a partner to strengthen its corporate practice

O’Melveny, Grandall, Carey Olsen, HSF and Jia Yuan assisted Tiantu Capital in completing its USD144 million IPO on HKEX, making it the first mainland PE/VC company to list in the city

O’Melveny, Han Kun Law Offices, Maples Group, Latham & Watkins and Zhong Lun Law Firm advised on cancer drug developer Adlai Nortye’s Nasdaq debut

China’s AI unicorn Fourth Paradigm, after three previous attempts, has successfully listed on the HKEX raising HKD1.02 billion (USD130 million)

Luzhu Biotechnology debuted on the HKEX through chapter 18A, the first biotech company without any revenue or profits to be listed this year, raising USD43.45 million

Morrison Foerster has expanded its private equity and M&A operation in China with the hiring of partner Zhao Rongjing from Kirkland & Ellis

O’Melveny advised China’s medical technology company, Acotec Scientific Holdings, on the voluntary partial offer for a majority stake of up to 65% by US-listed Boston Scientific Group

3D Medicines, an oncology medical research and development company, tapped Han Kun Law Firm’s intellectual property services during preparations for its HKD430 million Hong Kong IPO, to protect multiple patented drugs

Gaush Meditech, the fourth largest ophthalmic medical device company in China, raised HKD672 million (USD86.34 million) in its Hong Kong listing, offering a total of 13.06 million shares at HKD51.4 per share

China Business Law Journal reveals the law firms that have excelled in the past year